NervGen Pharma Corp. (NGEN) stock
Close on Nov 16, 2026Market cap $144.96MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- C$206.66M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -0.61 CAD
Trading
- Previous close
- $1.88
- Open
- $1.85
- Day's range
- $1.75 – $2.08
- Volume
- 1,622,545
- Average volume (20 days)
- 655,913
- RSI (14 days)
- 64.1
- Volatility (1 year)
- 85.7%
- Relative volume
- 2.85×
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | NGEN | S&P 500 | Difference | NGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +14.5% | -3.1% | +17.5 pts | ||
| 3 months | +4.9% | -4.5% | +9.3 pts | ||
| Year to date | -67.5% | +9.4% | −76.9 pts | ||
| 1 year | -22.9% | +11.3% | −34.2 pts | ||
| 3 years | +30.9% | +70.4% | −39.5 pts | +9.4% | +19.4% |
| 5 years | -22.7% | +68.6% | −91.3 pts | -5.0% | +11.0% |
| 10 years | +18100.0% | +297.7% | +17802.3 pts | +68.3% | +14.8% |
Three years at a glance
Fiscal years 2023 to 2025, CAD
EPS, diluted
Press releases
Releases NervGen Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About NervGen Pharma
Pharmaceutical Preparations
NervGen Pharma Corp. is a pharmaceutical company based in Canada that engages in scientific research and experimental development. The company focuses its operational efforts on preclinical development, clinical and regulatory activities, chemistry manufacturing and controls, and the licensing and protection of patents. Operating as a development-stage enterprise within the pharmaceutical preparations industry, the business does not report distinct commercial operating segments or commercial product sales to external customers. Its core activities center on proprietary research, development initiatives, and related advisory work directed by executive leadership and medical advisors.
Company profile, executives and historyNervGen Pharma stock: common questions
What is NervGen Pharma's stock price?
NGEN closed at $1.82 on Nov 16, 2026, down 3.19% on the day.
What is NervGen Pharma's market cap?
NervGen Pharma was worth $144.96M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is NGEN's P/E ratio?
NervGen Pharma lost money over fiscal 2025 (diluted EPS -0.61 CAD), so it has no meaningful P/E ratio.
Does NervGen Pharma pay a dividend?
No. NervGen Pharma has not paid a cash dividend over the last twelve months.
How has NGEN stock performed over the past year?
Including dividends, NGEN returned -22.9% over the past year, against +11.3% for the S&P 500.
Who are NervGen Pharma's competitors?
Companies most similar to NervGen Pharma by business, industry and size include HELP, DRUG, MSLE, CMND, MTRI.
See a number that looks wrong?